CEL-SCI's Multikine gains Saudi accelerated review designation for potential 2027 launch
CVM•
CVM•CEL-SCI said Saudi Arabia’s food and drug authority designated investigational cancer immunotherapy Multikine for accelerated review. The company plans to submit a marketing application within two to three months, with sales potentially starting in 2027 or early 2028 if approved.
CEL-SCI announced on November 20, 2026, that the Saudi Food and Drug Authority designated Multikine for accelerated review. A marketing application is planned within two to three months, and the pathway has a target assessment period of 160 working days.
Saudi Arabia could become Multikine’s first commercial market, with sales potentially starting in 2027 or early 2028, subject to regulatory approval. Local partner Amarox has exclusive Saudi distribution rights under a 50%/50% net revenue-sharing agreement. Previously reported Phase 3 results showed improved survival versus standard care alone among previously untreated oral cancer patients in the targeted population.